Professor Ruth Plummer Dr Christopher Jones Professor Nicola Curtin Professor Alan Boddy Professor Herbie Newell et al. | Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors | 2008 |
|
Professor Ruth Plummer Professor Alan Boddy Professor Nicola Curtin Professor Herbie Newell Lynsey Robson et al. | Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide | 2005 |
|
Professor Ruth Plummer Dr Christopher Jones Lynsey Robson Professor Alan Calvert
| First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors | 2005 |
|
Dr Mark Verrill Professor Alan Boddy Julieann Sludden Kevin Fishwick Lynsey Robson et al. | Phase 1 pharmacokinetic (PK) study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors | 2003 |
|
Professor Alan Boddy Dr Mark Verrill Julieann Sludden Kevin Fishwick Lynsey Robson et al. | Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study | 2002 |
|
Professor Alan Boddy Dr Mark Verrill Julieann Sludden Melanie Griffin Kevin Fishwick et al. | Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)-paclitaxel conjugate | 2001 |
|
Professor Alan Boddy Huw Thomas Lynsey Robson Professor Alan Calvert
| A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer | 1997 |
|
Professor Alan Boddy Huw Thomas Professor Herbie Newell Professor Alan Calvert Lynsey Robson et al. | Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: A cancer research campaign phase I/II committee study | 1996 |
|
Kevin Fishwick Lynsey Robson Professor Alan Calvert
| Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer | 1996 |
|
Professor Alan Calvert Professor Alan Boddy Dr Andrew Hughes Lynsey Robson Huw Thomas et al. | Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. | 1995 |
|
Lynsey Robson Professor Alan Calvert
| Oral folic acid improves lometrexol toxicity profile: A phase I study | 1995 |
|